Department of Nutrition & Biochemistry, Sabzevar University of Medical Sciences, Sabzevar, Islamic Republic of Iran.
Ren Fail. 2011;33(9):892-8. doi: 10.3109/0886022X.2011.605536. Epub 2011 Aug 23.
Lipid abnormalities, especially high serum lipoprotein (a) [Lp (a)] concentration, and anemia are two major causes of cardiovascular diseases (CVDs) in hemodialysis patients. Therefore, this study was designed to investigate the effects of marine omega-3 fatty acids on serum lipids, Lp (a), and hematologic factors in hemodialysis patients.
Thirty-four hemodialysis patients were randomly assigned to either omega-3 fatty acid supplement or placebo group. Patients in the omega-3 fatty acids group received 2080 mg marine omega-3 fatty acids, daily for 10 weeks, whereas the placebo group received a corresponding placebo. At baseline and the end of week 10, 7 mL blood was collected after a 12- to 14-h fast and serum triglyceride, total cholesterol, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), Lp (a), blood hemoglobin, hematocrit, red blood cells (RBCs), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), and mean corpuscular hemoglobin concentration (MCHC) were measured.
Serum triglyceride decreased significantly in the omega-3 fatty acids group at the end of week 10 compared with baseline (p < 0.05) and this reduction was significant in comparison with the placebo group (p < 0.01). No significant differences were observed between the two groups in mean changes of serum total cholesterol, LDL-C, HDL-C, Lp (a), blood hemoglobin, hematocrit, RBC, MCV, MCH, and MCHC.
The results of our study indicate that marine omega-3 fatty acids can reduce serum triglyceride, as a risk factor for CVD, but it does not affect other serum lipids, Lp (a), and hematologic factors in hemodialysis patients.
脂质异常，尤其是血清脂蛋白（a）[Lp（a）]浓度升高，以及贫血是血液透析患者发生心血管疾病（CVD）的两个主要原因。因此，本研究旨在探讨海洋 ω-3 脂肪酸对血液透析患者血脂、Lp（a）和血液学因素的影响。
34 名血液透析患者被随机分配到 ω-3 脂肪酸补充剂组或安慰剂组。ω-3 脂肪酸组患者每天服用 2080mg 海洋 ω-3 脂肪酸，持续 10 周，而安慰剂组服用相应的安慰剂。在基线和第 10 周末，禁食 12-14 小时后采集 7mL 血液，测量血清甘油三酯、总胆固醇、低密度脂蛋白胆固醇（LDL-C）、高密度脂蛋白胆固醇（HDL-C）、Lp（a）、血红蛋白、血细胞比容、红细胞（RBC）、平均红细胞体积（MCV）、平均红细胞血红蛋白（MCH）和平均红细胞血红蛋白浓度（MCHC）。
与基线相比，ω-3 脂肪酸组患者在第 10 周末的血清甘油三酯显著降低（p<0.05），与安慰剂组相比，这种降低具有显著差异（p<0.01）。两组患者血清总胆固醇、LDL-C、HDL-C、Lp（a）、血红蛋白、血细胞比容、RBC、MCV、MCH 和 MCHC 的平均变化均无显著差异。
我们的研究结果表明，海洋 ω-3 脂肪酸可降低 CVD 的风险因素血清甘油三酯，但对血液透析患者的其他血脂、Lp（a）和血液学因素没有影响。
